Clinical trial
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic…
NCT00103701 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00103701 |
|---|---|
| Title | BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
| Official title | Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic-phase, Lymphoblastic, Acute, Philadelphia-positive |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Start date | Nov 1, 2003 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Feb 15, 2005 |
| Last update posted | Apr 14, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: